

Finding Balance in Your Starting Material

Purity and Yield

QUALITY BEGINS WITH DONORS

Bringing successful cellular therapeutics to market can be expedited with the use of high-quality starting materials that minimize downstream processing. Though the collection of a high-quality starting material involves many steps, expertise in donor management and apheresis collection experience are areas which impact quality most significantly. With a wealth of experience, trust HemaCare to provide you with the quality product you need to bring your therapeutic to market quicker.

Donor Management

The Impact of Donor Variability

Donors lifestyle choices and personal issues can affect their physiology and introduce variability in the collection process. Collection-to-collection variability is frustrating, but often an uncontrollable event. Changes in diet, stress, alcohol intake, sleep, etc. can all affect the total nucleated cell yield from a donor.



Donor Recruitment

Dedicated team screens 100's of new donors monthly adding to multiple donor pools based on qualifying criteria.

HemaCare Donation Allowance

Whole Blood	Every 8 weeks
Bone Marrow	3 times per year with a 20 lifetime max
Leukopak	Every 5 weeks
Mobilized Leukopak	Twice in a lifetime



Donor Nurturing

Continuous follow up to advise potential donors on positive habits and practices to maximize donation yield.



Donor Safety

Keeping in mind donor comfort and safety, HemaCare has strict guidelines limiting the total blood volume processed and in turn the time a donor is on the bed.

Experience Matters

Years of Experience



Apheresis Collections



Apheresis Experience

Even the most state-of-the-art equipment needs fine tuning, and the expertise required to adjust parameters appropriately is only gained with experience and training. Every collection is closely managed by an experienced apheresis expert to ensure the perfect balance of purity and yield is obtained.

Donor Networks

HemaCare's significant experience with donor center operations is unparalleled. We know the importance of maintaining strong, positive relationships with our donors. Providing a pleasant donation experience is critical to the development of a robust donor network that is recallable - only satisfied donors will return reliably. The size of our donor network can support even the most stringent inclusion and exclusion criteria for general research, mobilized, or GMP projects.



Combined Years of Clinical Experience



Combined Years of Donor Center Experience

Purity AND Yield

We strive to obtain the highest possible yield from every collection. Though yield is certainly a priority, purity of the product will never be sacrificed - the key is to find the perfect balance. A common misconception is that lower yield equals lower quality. This is not true.

Donor variability can result in collections with lower yields but high purity [low hematocrit and granulocyte contamination]. This is a high-quality starting material. In cases where naturally low yields are physiologically normal, manipulation of the apheresis process to increase donor yield is inadvisable. This leads to impurities that increase downstream processing complexity and cost.

Quality of a HemaCare Leukopak

11.9B

Median Yield

99.2%


Median Viability

0.93%

Median Red Cell Contamination

2.25%

Median Granulocyte Contamination



Numbers are medians based on a recent analysis of HemaCare fresh leukopaks. Average total blood volume processed is 9 liters.

Finding the Balance